MedTrace Logo

Red-fleshed Apple as a Novel Anthocyanin-biofortified Food to Improve Cardiometabolic Risk Factors.

NCT03795324 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2019-01-07

No results posted yet for this study

Summary

The primary aim is to evaluate the added health value of the presence of anthocyanins in the redlove apple, versus a green apple with a similar matrix, on cardiometabolic risk, and compare the matrix effect on the bioavailability of anthocyanins, and its effect on cardiometabolic risk factors, in two different products with a similar phenolic and anthocyanin content: the redlove apple and an aronia drink.

Conditions

  • High LDL-cholesterol Levels

Interventions

OTHER

Redlove Apple intervention

The bioactive compounds present in this product are anthocyanins (50mg per 80g of product).It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized redlove apple.

OTHER

Green Apple intervention

It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized green apple.

OTHER

Aronia drink intervention

The bioactive compounds present in this extract are anthocyanins (50mg per 1L of water).It was a 6 weeks nutritional intervention. Volunteers will drink 1L per day of an aronia drink

Sponsors & Collaborators

  • Universitat de Lleida

    collaborator OTHER

  • Ministerio de Ciencia e Innovación, Spain

    collaborator OTHER_GOV

  • University Rovira i Virgili

    lead OTHER

Principal Investigators

  • Rosa Sola, MD, PhD · University Rovira i Virgili

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2019-12-31
Completion
2020-02-29

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03795324 on ClinicalTrials.gov